{"id":40080,"date":"2026-05-20T10:06:47","date_gmt":"2026-05-20T08:06:47","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=40080"},"modified":"2026-05-13T15:55:14","modified_gmt":"2026-05-13T13:55:14","slug":"evolocumab-primaerpraevention-kardiovaskulaerer-ereignisse-bei-diabetikern-ohne-signifikante-atherosklerose-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/evolocumab-primaerpraevention-kardiovaskulaerer-ereignisse-bei-diabetikern-ohne-signifikante-atherosklerose-cme","title":{"rendered":"Evolocumab: Prim\u00e4rpr\u00e4vention kardiovaskul\u00e4rer Ereignisse bei Diabetikern ohne signifikante Atherosklerose [CME]"},"content":{"rendered":"<p>Wir haben in der Januarausgabe 2026 \u00fcber die VESALIUS-CV-Studie berichtet ,\u00a0. In M\u00e4rz 2026 wurden die Ergebnisse einer Subgruppe ver\u00f6ffentlicht: Evolocumab (Repatha\u00ae) soll demnach schwerwiegende kardiovaskul\u00e4re Ereignisse (Major cardivascular events = MACE) bei Patienten mit Diabetes mellitus ohne signifikante Atherosklerose im Rahmen der Prim\u00e4rpr\u00e4vention besser als ein Statin allein verhindern . Die doppelblinde, placebokontrollierte RCT [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben in der Januarausgabe 2026 \u00fcber die VESALIUS-CV-Studie berichtet ,\u00a0. In M\u00e4rz 2026 wurden die Ergebnisse einer Subgruppe ver\u00f6ffentlicht: Evolocumab (Repatha\u00ae) soll demnach schwerwiegende kardiovaskul\u00e4re Ereignisse (Major cardivascular events = MACE) bei Patienten mit Diabetes mellitus ohne signifikante Atherosklerose im Rahmen der Prim\u00e4rpr\u00e4vention besser als ein Statin allein verhindern . Die doppelblinde, placebokontrollierte RCT [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,48,3065,71,453,498,456,65,1525,1526,1522,6319],"class_list":["post-40080","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-diabetes-mellitus","tag-evolocumab","tag-herzinfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-pcsk9","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-vesalius-cv-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=40080"}],"version-history":[{"count":3,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40080\/revisions"}],"predecessor-version":[{"id":40083,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40080\/revisions\/40083"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=40080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=40080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=40080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}